Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Naomi Cornish et al, adding:
”Associations of Tumor Somatic Mutations with Cancer-Associated Venous Thromboembolism
Analysis of 12,507 cancer patients reveals that somatic mutations in CDKN2A, KRAS, PCDH15, and TP53 significantly increase VTE risk, while high tumor mutational burden is protective, offering novel insights into cancer-associated thrombosis pathophysiology and future risk prediction tools.”
Title: Associations of tumor somatic mutations with cancer-associated venous thromboembolism
Authors: Naomi Cornish, Rebecca Ward, Matthew T. Warkentin, Chrissie Thirlwell, Andrew D. Mumford, Sarah K. Westbury, Philip C. Haycock
Read the Full Article on JTH

Stay updated on all scientific advances with Hemostasis Today.
-
May 18, 2026, 14:47Ting Yuan: Understanding the Complexity Behind Repeated IVF Failure
-
May 18, 2026, 14:33Global Resolution on Advancing Comprehensive Care and Health Equity for People with Bleeding Disorders Worldwide at the 79th WHA – WFH
-
May 18, 2026, 14:25Salih Ehsan: Key Diagnostic Clues in Thalassemia Minor
-
May 18, 2026, 14:02Matteo Foschi: A Global Gathering for Stroke Innovation and Research at ESOC 2026
-
May 18, 2026, 14:01Who is the NBA? – Haemophilia Foundation Australia
-
May 18, 2026, 14:00Julie Makani: Partnership between Tanzania and the USA – Health Sciences
-
May 18, 2026, 13:58Alejandro González Veliz: Cardiology Enters the Era of Inflammation
-
May 18, 2026, 13:50Arshad-Ali Auhammad: Celebrating Youth Leadership in the Global Bleeding Disorders Community
-
May 18, 2026, 13:36Zain Khalpey: In Cardiovascular Medicine Flow Is Everything